Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965558 | 0.78 | CA1 (0.37) | CA1CA2CA9 | |
| SCHEMBL1148252 | 0.73 | — | — | |
| SCHEMBL24445900 | 0.72 | — | — | |
| SCHEMBL1128365 | 0.71 | — | — | |
| SCHEMBL1447898 | 0.71 | — | — | |
| SCHEMBL1448054 | 0.71 | — | — | |
| SCHEMBL2107930 | 0.69 | — | — | |
| SCHEMBL14814117 | 0.69 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL25435567 | 0.69 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL3038772 | 0.69 | TDP1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102473961-B | Electrolyte including amide compound and electrochemical device including the same | LG CHEMICAL LTD | 2015-04-29 | — | — | CN | claimed |
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | claimed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | claimed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | claimed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | claimed |
| US-12628589-B2 | Etching method using oxygen-containing hydrofluorocarbon | L'Air Liquide, Societé´ Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) | 2026-05-12 | — | — | US | disclosed |
| WO-2024178284-A1 | ETCHING METHOD USING OXYGEN-CONTAINING HYDROFLUOROCARBON | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2024-08-29 | — | — | WO | disclosed |
| US-20240290628-A1 | ETCHING METHOD USING OXYGEN-CONTAINING HYDROFLUOROCARBON | AMERICAN AIR LIQUIDE, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240290627-A1 | ETCHING METHOD USING OXYGEN-CONTAINING HYDROFLUOROCARBON | AMERICAN AIR LIQUIDE, INC. (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024178258-A1 | ETCHING METHOD USING OXYGEN-CONTAINING HYDROFLUOROCARBON | L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) | 2024-08-29 | — | — | WO | disclosed |
| US-6909013-B2 | Process for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20050113581-A1 | Process for the preparation of carboxylic acid esters | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-26 | — | — | US | disclosed |
| US-20020151741-A1 | Process for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-17 | — | — | US | disclosed |
| EP-1227077-A2 | Process for producing cyclopropanecarboxylates | Sumitomo Chemical Co.,Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0888270-B1 | DIHALOPROPENE COMPOUNDS, THEIR USE AS INSECTICIDES/ACARICIDES AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6140274-A | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113581-A1 | Process for the preparation of carboxylic acid esters | ACSL6, ALKBH3, ACSL1 | CA1 544/4885CA2 531/4885CA9 139/4885 |
| US-20020151741-A1 | Process for producing cyclopropanecarboxylates | CYC1, CYP21A2, CYP2A6 | CA1 91/4885CA2 166/4885CA9 110/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | CA1 2788/4885CA2 384/4885CA9 833/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CA1 4815/4885CA2 3116/4885CA9 2648/4885 |
| US-12628589-B2 | Etching method using oxygen-containing hydrofluorocarbon | HAO2, HYOU1, ZYX | CA1 63/4885CA2 157/4885CA9 557/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | CA1 2350/4885CA2 466/4885CA9 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.